A5079103223- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Cytomegalovirus and herpesvirus research
- Polyomavirus and related diseases
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Renal Transplantation Outcomes and Treatments
- Transplantation: Methods and Outcomes
- T-cell and B-cell Immunology
- Immunodeficiency and Autoimmune Disorders
- Chronic Myeloid Leukemia Treatments
- Viral-associated cancers and disorders
- Neutropenia and Cancer Infections
- Virus-based gene therapy research
- Mesenchymal stem cell research
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Immunotherapy and Immune Responses
- Blood disorders and treatments
- Herpesvirus Infections and Treatments
- Brain Metastases and Treatment
- Organ Transplantation Techniques and Outcomes
- Platelet Disorders and Treatments
Memorial Sloan Kettering Cancer Center
2016-2025
Cornell University
2011-2023
Weill Cornell Medicine
2021-2023
Presbyterian Hospital
2017-2018
New York Hospital Queens
2017-2018
NewYork–Presbyterian Hospital
2017-2018
Kettering University
2016
Leukemia Research Foundation
2011
New York Blood Center
2011
Pediatrics and Genetics
2005-2011
Lymphoma associated with Epstein-Barr virus (EBV) is a complication of bone marrow transplantation that responds poorly to standard forms therapy. The lymphoma usually donor origin. We hypothesized treatment infusions leukocytes, which contain cytotoxic T cells presensitized EBV, might be an effective treatment.
Allogeneic bone marrow transplantation is curative in a substantial number of patients with hematologic cancers, marrow-failure disorders, immunodeficiency syndromes, and certain metabolic diseases. Unfortunately, only 25 to 30 percent potential recipients have HLA-identical siblings who can act as donors. In 1986 the National Marrow Donor Program was created United States facilitate finding procurement suitable from unrelated donors for lacking related donors.During first four years...
Congenital agranulocytosis is a disorder characterized by severe neutropenia and profound deficiency of identifiable neutrophil progenitors in bone marrow. In an attempt to stimulate production thereby reduce the morbidity mortality associated with this disease, we administered recombinant human granulocyte colony-stimulating factor (rhG-CSF) doses 3 60 micrograms per kilogram body weight day five patients congenital agranulocytosis. all patients, increase number neutrophils was noted eight...
Chimeric antigen receptor (CAR) T cells have demonstrated clinical benefit in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We undertook a multicenter trial to determine toxicity, feasibility, and response for this therapy. A total of 25 pediatric/young adult (age, 1-22.5 years) R/R B-ALL were treated 19-28z CAR cells. Conditioning chemotherapy included high-dose (3 g/m2) cyclophosphamide (HD-Cy) 17 low-dose (≤1.5 (LD-Cy) 8 patients. Fifteen had...
BACKGROUND. Adoptive transfer of donor-derived EBV-specific cytotoxic T-lymphocytes (EBV-CTLs) can eradicate EBV-associated lymphomas (EBV-PTLD) after transplantation hematopoietic cell (HCT) or solid organ (SOT) but is unavailable for most patients.
BONE marrow from unrelated donors is increasingly being transplanted for the treatment of patients with leukemia, aplastic anemia, and lethal congenital disorders hematopoiesis immunologic function. National international registries HLA-typed volunteer have been developed to optimize HLA matching between recipients.1 , 2 The fate grafts depends on many factors, including conditioning regimens, composition cells in graft, immunosuppression after transplantation, degree histocompatibility...
Clinical trials with bone marrow depleted of donor T lymphocytes indicate that both the incidence and severity graft-versus-host disease (GVHD) in patients undergoing transplantation (BMT) for treatment leukemia are greatly reduced. However, there has been a concurrent increase graft rejection, particularly among recipients HLA-nonidentical grafts. In order to investigate nature failure, peripheral blood mononuclear cells (PBMC) present at time failure have characterized by phenotypic...
Ninety-seven children with either acute lymphoblastic leukemia (ALL) or myelogenous (AML) received HLA-identical bone marrow transplants from sibling donors, after preparation 1320 cGy of hyperfractionated total-body irradiation and high-dose cyclophosphamide. Kaplan–Meier product–limit estimates (means ±SE) disease-free survival at five years among patients ALL in second remission, third fourth remission relapse were 64±9, 42±14, 23±11 percent, respectively, probabilities 13±7, 25±13, 64±16...
Therapeutic options for severe hepatic veno-occlusive disease (VOD) are limited and outcomes dismal, but early phase I/II studies have suggested promising activity acceptable toxicity using the novel polydisperse oligonucleotide defibrotide. This randomized II dose-finding trial determined efficacy of defibrotide in patients with VOD following hematopoietic stem cell transplantation (HSCT) identified an appropriate dose future trials. Adult pediatric received either lower-dose (arm A: 25...
Clinical trials with bone marrow depleted of donor T lymphocytes indicate that both the incidence and severity graft-versus-host disease (GVHD) in patients undergoing transplantation (BMT) for treatment leukemia are greatly reduced. However, there has been a concurrent increase graft rejection, particularly among recipients HLA-nonidentical grafts. In order to investigate nature failure, peripheral blood mononuclear cells (PBMC) present at time failure have characterized by phenotypic...
The Cord Blood Transplantation Study (COBLT), sponsored by the National Heart, Lung, and Institute, is a phase II multicenter study designed to evaluate use of cord blood in allogeneic transplantation. In this report, we evaluated outcomes transplantation 69 patients with lysosomal peroxisomal storage diseases. Patients mucopolysaccharidoses I III, mucolipidoses (ML) (n = 36), adrenoleukodystrophy 8), metachromatic leukodystrophy 6), Krabbe disease 16), Tay-Sachs 3) were enrolled between...